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Abstract
Background: The function of endothelial progenitor cells (EPCs), which are key cells in vascular
repair, is impaired in diabetes mellitus. Nitric oxide (NO) and reactive oxygen species can regulate
EPC functions. EPCs tolerate oxidative stress by upregulating superoxide dismutase (SOD), the
enzyme that neutralizes superoxide anion (O2
-). Therefore, we investigated the roles of NO and
SOD in glucose-stressed EPCs.
Methods: The functions of circulating EPCs from patients with type 2 diabetes were compared to
those from healthy individuals. Healthy EPCs were glucose-stressed, and then treated with insulin
and/or SOD. We assessed O2
- generation, NO production, SOD activity, and their ability to form
colonies.
Results: EPCs from diabetic patients generated more O2
-, had higher NAD(P)H oxidase and SOD
activity, but lower NO bioavailability, and expressed higher mRNA and protein levels of p22-phox,
and manganese SOD and copper/zinc SOD than those from the healthy individuals. Plasma glucose
and HbA1c levels in the diabetic patients were correlated negatively with the NO production from
their EPCs. SOD treatment of glucose-stressed EPCs attenuated O2
- generation, restored NO
production, and partially restored their ability to form colonies. Insulin treatment of glucose-
stressed EPCs increased NO production, but did not change O2
- generation and their ability to
form colonies. However, their ability to produce NO and to form colonies was fully restored after
combined SOD and insulin treatment.
Conclusion:  Our data provide evidence that SOD may play an essential role in EPCs, and
emphasize the important role of antioxidant therapy in type 2 diabetic patients.
Background
Hyperglycemia impairs vascular endothelial function, and
contributes to the vasculopathies of diabetes mellitus,
even with tight glycemic control [1]. Endothelial progeni-
tor cells (EPCs) are circulating cells that originate from the
bone marrow, and promote neovascularization at sites of
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ischemia, hypoxia, injury, or tumor formation [2]. Emerg-
ing evidence suggests that there is a negative correlation
between the severity of diabetes and EPC count and func-
tion [3,4].
The complex pathophysiology of vascular damage in dia-
betes is not fully understood. EPC dysfunction in type 2
diabetic patients is linked to excessive generation of reac-
tive oxygen species and oxidative stress [5]. Reduced extra-
cellular superoxide dismutase (SOD) activity, also known
as copper/zinc SOD (Cu/ZnSOD) is associated with
increased vascular oxidative stress, and has been impli-
cated in the endothelial dysfunction of patients with
hypertension, congestive heart failure, and coronary
artery disease [6]. It has been reported that human EPCs
can tolerate oxidative stress because they have high intra-
cellular expression levels of manganese SOD (MnSOD),
the enzyme which scavenges superoxide anion (O2
-) [7,8].
Nitric oxide (NO) is a biologically active unstable radical
that is synthesized in vascular endothelial cells by NO
synthase (eNOS), and its bioavailability depends on the
balance between its production and inactivation rates [9].
Decreased NO bioavailability has been proposed as one
of the determinants of vascular damage in diabetes. NO
can stimulate EPC mobilization from bone marrow stem
cell niches to the peripheral circulation so that they can
participate in the neovascularization process [10]. Chen
and colleagues reported that prolonged exposure of early
and late EPCs to high glucose (HG) concentrations
reduces their number and proliferative ability, NO bioa-
vailability, and the extent of phosphorylation of eNOS
and some members of the PI3-kinase/Akt signaling path-
way [11]. Exposure of EPCs to HG concentrations
increases NAD(P)H oxidase activity which results in
increased O2
- generation and reduced NO bioavailability
because O2
- inactivates NO and uncouples eNOS [12].
Sorrentino and colleagues demonstrated that NO bioa-
vailability and the in vivo reendothelialization capacity of
EPCs from diabetic patients can be restored by inactivat-
ing NAD(P)H oxidase [13].
In the light of our current knowledge on the causes of EPC
dysfunction in type 2 diabetes, we hypothesized that pro-
longed exposure to hyperglycemia in type 2 diabetes leads
to excessive O2
-  generation which, in turn, adversely
affects the ability of EPCs to repair the vascular endothe-
lium. This study was undertaken to examine the effects of
HG concentrations on EPC function, and the role of SOD
in O2
- inactivation in glucose-stressed EPCs.
Methods
Clinical study protocol and subject characteristics
Twenty-three type 2 diabetic patients and 15 healthy age-
matched volunteers participated in this study. The
patients were selected from the Metabolic Outpatient
Clinic of the Rambam Health Care Campus, Haifa, Israel.
Clinical data for control participants and patients are pre-
sented in Table 1. Diagnosis of type 2 diabetes was the
only criterion for inclusion in this study, whereas exclu-
sion criteria included diagnosis of type 1 diabetes, and
presence of any of the following self-reported medical
conditions: recent surgery, auto-immune diseases, acute
or chronic infection and any other unrelated disease. The
control participants were selected randomly from healthy
volunteers. Medical histories were taken from, and clinical
laboratory examinations were performed on all healthy
volunteers to confirm that none had clinical or laboratory
evidence for diabetes, cardiovascular diseases, inflamma-
tory or auto-immune diseases, obesity or other chronic
diseases. The study was approved by the Ethics Commit-
tee of the Rambam Health Care Campus, and each partic-
ipant gave his/her written informed consent.
Table 1: Characteristics of the Study Participants
Characteristic Healthy
(n = 15)
Type 2 Diabetes
(n = 23)
Age (years) 56.3 ± 2.4 59.6 ± 1.5
Gender (M/F) 8/7 17/6
BMI, (kg/m2) 25.3 ± 1.2 29.7 ± 0.9**
Diabetes duration, (years) __ 12.2 ± 0.9
Clinical history
Smoking, n (%) 4 (27) 7 (30)
Hypertension, n (%) __ 11 (48)
CVD, n (%) __ 7 (30)
Retinopathy, n (%) __ 2 (9)
Nephropathy, n (%) __ 3 (13)
Neuropathy, n (%) __ 1 (4)
Clinical Laboratory Results
Plasma glucose levels, (mg/dl) 93.4 ± 2.4 221.8 ± 9.5***
HbA1c levels, (%) 4.7 ± 0.1 8.6 ± 0.3***
Total cholesterol, (mg/dl) 170.4 ± 8.4 178.6 ± 7.2
LDL-cholesterol, (mg/dl) 91.6 ± 3.2 107.9 ± 6.5
HDL-cholesterol, (mg/dl) 53.2 ± 1.5 51.4 ± 1.7
Triglyceride, (mg/dl) 109.5 ± 9.5 127.4 ± 13.2
Creatinine, (mg/dl) 0.77 ± 0.03 0.86 ± 0.04
Medications
Insulin, n (%) __ __
Oral antidiabetics, n (%) __ 23 (100)
-Rosiglitazone, n (%) __ 5 (22)
-Sulfonylureas, n (%) __ 11 (48)
-Metformin, n (%) __ 13 (57)
-Others, n (%) __ 4 (17)
-Combination, n (%) __ 6 (26)
ACEIs/ARBs, n (%) __ 7 (30)
Aspirin, n (%) __ 19 (82)
Statins, n (%) __ 12 (52)
Values are presented as mean ± SEM, or number (%) of subjects. 
Comparisons were made by two-tailed Student's unpaired t test or 
Mann-Whitney test, for non-parametric data. Smokers refer to 
previous or current smokers. Statistical significance, *P < 0.05, **P < 
0.001, ***P < 0.001 versus healthy.Cardiovascular Diabetology 2009, 8:56 http://www.cardiab.com/content/8/1/56
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The medical history, results of previous clinical laboratory
tests, and medications were obtained from diabetic
patient's medical files upon recruitment. Age, gender,
BMI, diabetes duration, smoking habit, and the presence
of clinical state associated with diabetes complications
including hypertension, cardiovascular diseases (CVD),
retinopathy, nephropathy, neuropathy, and medication
history were recorded (Table 1). All participants under-
went a complete metabolic evaluation. Peripheral blood
samples (50 mL) were collected from all participants for
ex vivo EPC assessment, and measurement of plasma glu-
cose and HbA1c levels.
Isolation, cultivation and characterization of EPCs
EPCs were isolated cultured and characterized, as
described previously [14]. Peripheral blood mononuclear
cells (MNCs) were isolated by density gradient centrifuga-
tion using Lymphoprep™ (Axis-Shield, Oslo, Norway),
and then grown in endothelial cell basal medium-2
(EBM-2) (PromoCell GmbH, Heidelberg, Germany) for
five days. The EPCs in the cultures were identified as
adherent cells that stained double positive for acetylated
LDL (acLDL) uptake and the binding of FITC-labeled lec-
tin under a laser scanning confocal microscope. For this
purpose, the adherent cells from the EPC cultures were
first incubated with 2.2 μg/mL 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine-labeled acLDL (Biomedical
Technologies, Inc., MA, USA) for two hours at 37°C. After
two hours, the cells were fixed in 2% paraformaldehyde,
and then counterstained with 10 μg/mL fluorescein iso-
thiocyanate-labeled lectin from Ulex europaeus agglutinin
(UEA-1) (Sigma Aldrich, MO, USA). The putative EPCs
were stained also for CD34 antigen (CHEMICON Inc.,
CA, USA), kinase-insert domain receptor (KDR), and
eNOS (R&D Systems, MN, USA) (Fig. 1a).
Determination of EPC count by flow cytometry
Circulating EPCs were analyzed for the expression of the
surface antigens CD34 and kinase insert domain receptor
(KDR) by two-color direct immunofluorescence flow
cytometry [15]. Isolated MNCs were stained with an FITC-
conjugated monoclonal antibody against human CD34
(MACS, Bergisch Gladbach, Germany) and a PE-conju-
gated monoclonal antibody against human KDR (R&D
Systems). Identical IgG isotype served as negative controls
(R&D Systems). The frequency of double-positive periph-
eral MNCs was determined by forward and side-scatter
fluorescence dot-plot analysis of a 5 × 105 cell sample
using a FACS Calibur analyzer (Becton Dickinson, NJ,
USA). Data were processed using the Macintosh CEL-
LQuest software program (Becton Dickinson).
Experimental protocols
Isolated EPCs from healthy volunteers were maintained in
EBM-2 with either 5.5 mmol/L D-glucose (NG) or 25
mmol/L D-glucose (HG) for five days before they were
used in the following two experimental protocols. High L-
glucose (25 mmol/L) was used as an osmolarity control.
Protocol 1
In order to establish whether NO production and O2
- gen-
eration were impaired in glucose-stressed EPCs, their NO
production and O2
- generation were compared to that
measured in non-stressed EPCs in the presence and
absence of 100 μM/mL L-NAME (a non-specific NOS
inhibitor) and 10 μM/mL apocynin (an NAD(P)H oxi-
dase inhibitor).
Endothelial progenitor cell characterization Figure 1
Endothelial progenitor cell characterization. Endothe-
lial progenitor cells (EPCs) were cultured for five days. (a) 
From left to right, Panel 1: acetylated LDL uptake by adher-
ent spindle-shaped EPCs, FITC-conjugated lectin UEA-1 bind-
ing to the surface of EPCs, and double-positive stained EPCs 
for acetylated LDL uptake and lectin binding. Panel 2: Immun-
ofluorescence detection of the CD34 antigen (red), and KDR 
(green) on the EPC surface. Panel 3: Immunofluorescence 
detection of eNOS in a single non-stained EPC (green). Panel 
4: Immunofluorescence detection of the CD34 antigen on 
the EPC surface (red), and eNOS (green). The EPC nuclei 
were stained with the blue fluorescent DNA dye DRAQ5™. 
Scale bare 50 μm. (b) A representative colony of EPCs with a 
central core of round cells that is surrounded by elongated 
spindle-shaped cells. Scale bare 100 μm.Cardiovascular Diabetology 2009, 8:56 http://www.cardiab.com/content/8/1/56
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Protocol 2
In order to establish whether the impaired NO production
of glucose-stressed EPCs could be restored by increasing
EPC glucose utilization or by exogenous SOD, the effects
of insulin, which is known to increase eNOS expression in
endothelial cells [15], and SOD supplementation on NO
production, O2
- generation, and their capacity to form col-
onies were determined by treating glucose-stressed EPC
with 100 μU/mL insulin for five days, 250 U/mL SOD for
two days, or 250 U/mL SOD and 100 μU/mL insulin for
two and five days.
EPC colony-forming unit counts
The ability of EPCs to form colonies was used as a marker
of proliferation [16]. An EPC colony-forming unit (CFU)
comprises a central core of round cells that is surrounded
by elongated spindle-shaped cells (Fig. 1b). The numbers
of colonies were counted manually after five days of EPC
culture, and expressed as the average number of CFUs per
well.
Measurement of NAD(P)H oxidase activity and O2
- 
generation
The generation of O2
- from EPCs was measured using a
lucigenin-enhanced chemiluminescence assay [17]. Cul-
tured EPCs (1 × 106 cells/ml) after the various treatments
were first lysed, and then 100 μM NAD(P)H in order to
generate O2
-, followed by 5 μM lucigenin were added to
each lysate. The amount of generated O2
- in each sample
was quantified by measuring the intensity in a fluores-
cence spectrophotometer, and was expressed as a percent-
age of that in the lysates of healthy or non-stressed EPCs.
NAD(P)H oxidase activity was measured in similar exper-
iments. Chemiluminescence was recorded every 15 s for
10 min. The lucigenin chemiluminescence was expressed
as counts per min per 106 cells. NAD(P)H (final concen-
tration 100 μmol/l) was added after measurement of
background lucigenin chemiluminescence and measure-
ment were performed for another 10 min. the difference
between the values obtained before and after adding
NAD(P)H was calculated and it represented the activity of
NAD(P)H oxidase, and was expressed as a percentage of
that in the lysates of healthy EPCs.
Measurement of SOD activity
The Superoxide Dismutase (SOD) Detection Kit™ (Cell
Technology Inc., CA, USA) was used to determine SOD
activity. After detaching and lysing the adherent EPCs,
aliquots (150 μl) of cell lysate were transferred to each
well of a 96-well microplate that contained tetrazolium
salt (WST-1) and xanthine oxidase, and then incubated at
37°C for 20 minutes. The rate of WST-1 formazan forma-
tion (inversely proportional to SOD activity) was then
measured in a microplate reader at OD440.
Measurement of NO production
NO production by cultured EPCs can be determined from
the NO content in the culture medium [18]. EPCs were
treated with either 5 μM bradykinin (Sigma) or 100 μM L-
arginine (Sigma) for 30 minutes at 37°C, and then 1 μM/
mL 4, 5-diaminofluorescein (DAF-2) (Cell Technology
Inc.) was added to the EPC cultures. NO content in the
EPC culture medium was then measured in a fluorescent
spectrophotometer at an excitation wavelength of 488 nm
and an emission wavelength of 515 nm. The NO content
in medium of the glucose-stressed EPCs was expressed as
the percentage of the NO content in the medium of the
unstressed EPCs.
Analysis of mRNA and protein expression
Total RNA was extracted from EPCs using the MasterPure
RNA purification kit (EPICENTER Biotechnologies, Madi-
son, WI, USA). For each sample, approximately 50 ng of
RNA were reversed transcribed in triplicate using Absolute
QPCR Mixes Reverse Transcription Reagents and the Verso
cDNA Reverse Transcriptase kit, both of which were pur-
chased from ABgene, UK. Real-time PCR was conducted
to examine the levels of human p22-phox; a membrane-
bound component of NAD(P)H oxidase, MnSOD and
Cu/ZnSOD in healthy and diabetic EPCs. Quantitative
amplification of the p22-phox, Cu/ZnSOD and MnSOD
cDNA was performed using SYBR Green I (Molecular
Probes, Eugene, OR) for 35 cycles that consisted of heat
denaturation, annealing and extension using Rotor-Gene
6000 (Corbett Life Science, Sydney, Australia). Levels of
human p22-phox, Cu/ZnSOD and MnSOD mRNA were
normalized against GAPDH mRNA and expressed as the
average of mean percentage of those from healthy EPCs.
Protein extracts for western blot analysis were prepared by
lysing EPCs from healthy and diabetic patients in RIPA
Lysis Buffer (Millipore, MA, USA) that contained a pro-
tease inhibitor. The lysates were resolved on SDS-PAGE
gels, and then transferred to polyvinyldene difluoride
membranes by electroblotting. The membranes were first
incubated with monoclonal antibodies against p22-phox,
Cu/ZnSOD and MnSOD (Santa Cruz, CA, USA), and then
with an appropriate horseradish peroxidase-conjugated
secondary antibody. An antibody against β-actin (Santa
Cruz) was used to normalize protein loading. The result-
ant bands were quantified by densitometry. The results
were expressed as the average of mean percentage of
lysates from healthy EPCs.
Statistical analysis
Data are expressed as mean value or percentage ± standard
error of the mean (SEM). The unpaired Student's t test was
used to compare the data from two groups, and one-way
analysis of variance was used when there were more than
two groups. Pearson's correlation coefficient was used toCardiovascular Diabetology 2009, 8:56 http://www.cardiab.com/content/8/1/56
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determine the relationships between NO production and
O2
- generation by the patient's EPCs, and his/her individ-
ual plasma glucose and HbA1c levels, and between SOD
activity, and O2
- generation and NO production. Relation-
ships between risk factors or medications and NO produc-
tion from EPCs were examined by multivariate analysis.
The level of statistical significance was set at 5%. A com-
puterized statistical software program (Prism version 5.0,
GraphPad, CA, USA) was used to analyze the data.
Results
Effect of diabetes on EPC
Plasma glucose and HbA1c levels, and BMI in the diabetic
patients were significantly higher than those in the
healthy volunteers (Table 1). The circulating EPC count of
diabetic patients and the proliferative ability of the EPCs
were significantly lower than those of the EPCs from
healthy volunteers (Fig. 2a and Fig. 2b). EPCs of the dia-
betic patients produced less NO in response to bradykinin
stimulation than that produced by EPCs from healthy vol-
unteers (Fig. 2c). NAD(P)H oxidase activity (Fig. 2d), O2
-
generation (Fig. 2e) and SOD activity (Fig. 2f) in EPCs
from the diabetic patients were higher than those in EPCs
from healthy volunteers.
EPCs from diabetic patients express significantly higher
levels of p22-phox, and of the antioxidative enzymes Cu/
ZnSOD and MnSOD compared to EPCs from healthy vol-
unteers (Fig. 3a). The expression of p22-phox, Cu/ZnSOD
and MnSOD was further elucidated by western blot anal-
Endothelial progenitor cell number and function Figure 2
Endothelial progenitor cell number and function. Endothelial progenitor cells (EPCs) from diabetic patients and healthy 
individuals were cultured for five days. (a) Circulating EPCs were labeled with CD34 and KDR cell surface antigens, and then 
identified by flow cytometry. The bars represent the number of circulating EPCs in the two study groups. (b) The numbers of 
colony-forming units (CFUs) of EPCs were counted manually in the two study groups. (c) Nitric oxide (NO) content in the 
medium was determined by measuring the intensity of DAF-2 fluorescence in the EPC culture medium. (d) NAD(P)H oxidase 
activity in EPCs from type 2 diabetes patients and healthy individuals and (e) Superoxide anion (O2
-) generation by EPCs from 
type 2 diabetic patients and healthy individuals were measured by the lucigenin-enhanced chemiluminescence assay. (f) SOD 
activity in EPCs of type 2 diabetic patients and healthy individuals. The results in c, d, e, and f are expressed as a percentage of 
fluorescence intensity of the healthy group. Data are expressed as mean or percentage ± SEM. *P < 0.05, **P < 0.01, ***P < 
0.001. DM represents diabetic patients.Cardiovascular Diabetology 2009, 8:56 http://www.cardiab.com/content/8/1/56
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ysis. As shown in fig. 3b, the protein expression of p22-
phox, Cu/ZnSOD and MnSOD was significantly higher in
EPCs from diabetic patients compared with EPCs from
healthy volunteers (Fig. 3b).
Relationship between NO bioavailability in EPCs and 
diabetes
The plasma glucose and HbA1c levels in the diabetic
patients, and O2
- generation by their EPCs were correlated
negatively with NO production by their EPCs (Fig. 4a). In
contrast, SOD activity of the EPCs of diabetic patients was
correlated positively with O2
- generation by their EPCs,
but not with their NO production (Fig. 4b).
Of all risk factors that may affect NO production by EPCs,
diabetes was the only one that was significantly associated
with reduced NO production (Fig. 5a). Furthermore, we
found that increased NO production by EPCs was associ-
ated only with the use of statins by the diabetic patients
(Fig. 5b).
High glucose effects on EPCs
The proliferative capacity of EPCs was significantly
impaired in glucose-stressed EPCs when compared to that
of non-stressed EPCs (Fig. 6a). This impairment was not
due to an increase in osmolarity of the medium because
the proliferative capacity of non-stressed EPCs and those
exposed to L-glucose was the same.
Glucose-stressed EPCs generated significantly higher O2
-
levels than that in non-stressed EPCs. The increased O2
-
generation could be completely abrogated by apocynin
(Fig. 6b). SOD activity in glucose-stressed EPCs was signif-
icantly higher than that in non-stressed EPCs or EPCs that
were exposed to high L-glucose concentration. Treatment
of the glucose-stressed EPCs by apocynin decreased signif-
icantly SOD activity (Fig. 6c).
NO production by glucose-stressed EPCs was reduced sig-
nificantly when compared to that of non-stressed EPCs.
Apocynin treatment restored NO production, whereas L-
NAME treatment abrogated NO production (Fig. 6d).
The effect of insulin and SOD on glucose-stressed EPCs
The impaired NO production of glucose-stressed EPCs
was restored by adding either SOD, insulin, or both to the
EPC cultures (Fig. 7a). Treating glucose-stressed EPCs with
insulin had no effect on O2
- generation, whereas treating
mRNA and protein expression of SODs and p22-phox in EPCs Figure 3
mRNA and protein expression of SODs and p22-phox in EPCs. Total RNA and protein of EPCs from type 2 diabetic 
patients and healthy volunteers were isolated and the mRNA and the protein expressions of a membrane-bound component of 
NAD(P)H oxidase; p22-phox and the antioxidant enzymes; Cu/ZnSOD, and MnSOD were assessed. (a) Comparison of mRNA 
expression between p22-phox, Cu/ZnSOD, and MnSOD in EPCs of healthy volunteers (white bars) and type 2 diabetic 
patients (black bars). (b) Comparison of protein expression between p22-phox, Cu/ZnSOD, and MnSOD in EPCs of healthy 
volunteers (white bars) and type 2 diabetic patients (black bars). (c) Representative bolts. Blots were scanned and expression 
of p22-phox, Cu/ZnSOD, and MnSOD was quantified by densitometric analysis and normalized with β-actin. Data are 
expressed as mean or percentage ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. DM represents diabetic patients.Cardiovascular Diabetology 2009, 8:56 http://www.cardiab.com/content/8/1/56
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them with either SOD or SOD and insulin completely
abolished O2
- generation (Fig. 7b). The impaired prolifer-
ative ability of glucose-stressed EPCs was restored partly
by treating them with SOD, but not with insulin. Com-
plete restoration of this ability occurred when the glucose-
stressed EPCs were treated with insulin and SOD concom-
itantly (Fig. 7c).
Discussion
The main finding of this investigation is the important
role of SOD in modulating EPC function under hypergly-
cemic conditions. This conclusion is supported by our
finding that the addition of SOD restores NO production
and the proliferative ability of glucose-stressed EPCs. This
restorative action of SOD may be due to SOD scavenging
O2
-, thereby increasing NO bioavailability and/or pre-
venting the uncoupling of eNOS.
Reduced EPC counts and function are associated with
poor cardiovascular outcomes [16,19]. In uncontrolled
diabetes, reduced EPC count and functionality is associ-
ated with hyperglycemia [3,4]. Moreover, eNOS activity
and NO bioavailability in EPCs is reduced following pro-
longed exposure to hyperglycemia [11]. Ozuyaman and
colleagues demonstrated that EPC mobilization and func-
tion require NO [10]. In addition, Landmesser et al [20]
demonstrated that the improvement of EPC survival and
mobilization by statins requires eNOS in order to induce
myocardial neovascularization in mice. Therefore, it
seems that the NO which is produced by EPCs themselves
creates a favorite and optimal environment to promote
their mobilization and expansion.
Endothelial dysfunction is characterized by low bioavail-
ability of endothelium-derived NO which is itself an inde-
pendent predictor of future cardiovascular events. The
extent of the interaction between NO and O2
- is thought
to be important in the development of endothelial dys-
function because the resultant product, peroxynitrite, can
inactivate soluble guanylyl cyclase [21]. In addition,
Relationship between NO production and O2
-generation by EPCs, and the plasma glucose and HbA1c levels in type 2 diabetic  patients Figure 4
Relationship between NO production and O2
-generation by EPCs, and the plasma glucose and HbA1c levels in 
type 2 diabetic patients. (a) Scatter plot of the relationship between NO production and O2
- generation by EPCs from type 
2 diabetic patients and the individual patient's plasma glucose and HbA1c levels at the time of blood collection. (b) Scatter plot 
of the relationship between SOD activity in EPCs from type 2 diabetic patients and O2
- generation, and NO production of their 
EPCs.Cardiovascular Diabetology 2009, 8:56 http://www.cardiab.com/content/8/1/56
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increased generation and inadequate removal of O2
- can
result in oxidative stress, and the development of
endothelial dysfunction. The results of recent studies sug-
gest that reduced extracellular SOD activity is closely asso-
ciated with increased vascular oxidative stress, and has
been implicated in the endothelial dysfunction of patients
with hypertension [22], congestive heart failure, and cor-
onary artery disease [6]. Human EPCs have high intracel-
lular expression levels of MnSOD, and EPCs are
dependent on this level of expression to protect them-
selves against oxidative stress [7,8]. Tao and colleagues
demonstrated that augmenting Cu/ZnSOD expression in
human EPCs by shear stress can accelerate O2
- neutraliza-
tion. Indeed, they suggested that this O2
- neutralization
leads to increased local NO bioavailability, thereby
enhancing the EPC repair potential in the vascular system
[23].
We demonstrated that O2
- generation in glucose-stressed
EPCs is higher than that of non-stressed EPCs, and some
of this O2
-inactivated NO because the rate of NO produc-
tion increased after inhibiting NAD(P)H oxidase activity
with apocynin. We showed also that NAD(P)H oxidase
activity, O2
- generation and SOD activity are increased by
EPCs from the diabetic patients. Indeed, we found that
SOD activity of EPCs from diabetic patients was positively
correlated with their level of O2
- generation but not with
their level of NO production. The increased SOD activity
which accompanied the increased O2
- generation in these
EPCs may account for the intrinsic ability of EPCs to with-
stand the oxidative stress produced by O2
-. We confirmed
this correlation by demonstrating (a) an increase in
mRNA and protein expression of p22-phox and both Cu/
ZnSOD and MnSOD in EPCs from diabetic patients com-
pared with EPCs from healthy volunteers, and (b) a
decrease in SOD activity in glucose-stressed EPCs that
were treated with apocynin. In fact, inhibition of O2
- gen-
eration by inhibiting NAD(P)H oxidase activity with
apocynin confirms that high O2
- causes for increased SOD
activity in glucose-stressed EPCs. The EPCs of diabetic
patients remained however with low NO production and
high O2
- levels despite high SOD activity. The increased
SOD activity of the EPCs of diabetic patients may be not
sufficient to neutralize the high O2
-levels caused by diabe-
tes. We showed that there is a negative correlation
between plasma glucose levels and HbA1c levels and the
levels of NO production by EPCs from patients with dia-
betes. When plasma glucose levels and HbA1c levels
increase, less NO will be produced by the EPCs of the dia-
betic patients, and this may account for their increased
risk of developing cardiovascular disease. In addition, we
found that the level of O2
- generation by EPCs of diabetic
patients was inversely correlated with their level of NO
production. Increased generation of O2
- results in an aug-
mented interaction between O2
- and NO, which in turn
leads to accelerated inactivation of NO and its reduced
bioavailability in EPCs.
Glucose stress in EPCs could generate O2
- via several proc-
esses that include glucose auto-oxidation, increased pro-
tein kinase C and NAD(P)H oxidase activity [12]. For
example, inhibiting NAD(P)H oxidase activity in EPCs
from diabetic patients can restore their NO bioavailability
and function [13]. Accumulating data have shown that
statin therapy can inhibit NAD(P)H oxidase activation
and increase NO bioavailability in diabetes [24-26]. We
Effect of individual risk factors and medications on NO production from EPCs Figure 5
Effect of individual risk factors and medications on NO production from EPCs. (a) Effect of individual risk factors on 
NO production by EPCs of all diabetic patients. (b) Association between the individual medications that was taken by the type 
2 diabetic patients and NO production by their EPCs. Increased NO production by EPCs was associated with the use of statins 
only. Data are expressed as mean percentage ± SEM. *P < 0.05, **P < 0.01.Cardiovascular Diabetology 2009, 8:56 http://www.cardiab.com/content/8/1/56
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found that increased NO production by EPCs was associ-
ated only with the use of statins by the diabetic patients.
The increased O2
- generation by EPCs could be due to
either increased production of O2
-, exhaustion of the
enzymatic antioxidant systems, or both. Ohshima and
colleagues have demonstrated that antioxidant therapy
with SOD in diabetic mice reduced oxidative stress, and
increased their EPC count and potential to differentiate
into endothelial cells [27]. In our study, we showed that
treating glucose-stressed EPCs with SOD restored their
NO production and proliferative ability, and this result
suggests a protective role for SOD. However, it is possible
that adding SOD changed the balance between NO and
O2
-. Less NO was inactivated by O2
-, and the overall result
was an increase in NO bioavailability of EPCs.
In our study, we stimulated glucose utilization by EPCs
using insulin in order to highlight the role of SOD on NO
production by EPCs. Insulin enhances eNOS mRNA and
protein expression in endothelial cells without affecting
oxidative stress [28]. Therefore, we used insulin rather
than other antidiabetic drugs such as rosiglitazone,
because these drugs are reported to decrease NAD(P)H
oxidase activity and oxidative stress in endothelial cells
[29]. However, we found that insulin treatment did not
change O2
- levels in glucose-stressed EPCs but restored
Assessment of glucose-stressed EPC cultures Figure 6
Assessment of glucose-stressed EPC cultures. (a) Number of colonies (CFUs) of non-stressed EPCs (normal glucose (5 
mmol/L) (NG)), glucose-stressed EPCs (25 mmol/L D-glucose (HG)), and an osmolarity control (25 mmol/L L-glucose (LG)). 
(b) Superoxide anion (O2
-) generation in non-stressed and glucose-stressed EPCs in the absence or presence of apocynin. (c) 
SOD activity in non-stressed EPCs (NG), glucose-stressed EPCs (HG), glucose-stressed EPCs treated with apocynin, and an 
osmolarity control (25 mmol/L L-glucose (LG)). (d) NO levels in non-stressed EPCs (NG), glucose-stressed EPCs (HG), glu-
cose-stressed EPCs after being treated with apocynin, an inhibitor of NAD(P)H oxidase, and glucose-stressed EPCs after being 
treated with L-NAME, a non-specific inhibitor of NOS. Data are expressed as mean percentage ± SEM or mean number ± SEM 
of triplicate measurements in each sample from four independent tests. *P < 0.05, **P < 0.01, ***P < 0.001 vs. non-stressed 
EPCs (control). NS represents non-significant.Cardiovascular Diabetology 2009, 8:56 http://www.cardiab.com/content/8/1/56
Page 10 of 12
(page number not for citation purposes)
partially NO production. Although NO production in glu-
cose-stressed EPCs was enhanced by insulin, their prolif-
erative ability remained impaired. We propose that
insulin could not restore the proliferative ability of glu-
cose-stressed EPCs because of increased O2
- levels that was
not neutralized and which in turn decreases NO bioavail-
ability.
Although the exposure time of EPCs to HG concentrations
in our in vitro assays is much shorter than that of EPCs to
hyperglycemia in chronic diabetic patients, our finding
that treating glucose-stressed human EPCs with SOD
restored their functionality is in agreement with that of
Ohshima and colleagues in diabetic mice. Alterations in
either O2
- generation and/or SOD activity/expression can
markedly alter NO bioavailability in EPCs. Therefore,
SOD supplementation could be an excellent strategy to
reduce excessive O2
- production by EPCs and restore their
repair potential. Future studies whose aim is to explore
the effect of exogenous SOD supplementation on the
preservation of endothelial function in diabetes are
needed in order to confirm this suggestion.
Conclusion
The results of this study suggest that increased oxidative
stress plays an important role in EPC dysfunction in dia-
betes. We found evidence for separate, but complemen-
tary, effects of SOD and insulin treatment on the
functions of glucose-stressed EPCs. These findings empha-
size the important role of antioxidant therapy in diabetic
patients.
Insulin and SOD effects on glucose-stressed EPC cultures Figure 7
Insulin and SOD effects on glucose-stressed EPC cultures. Glucose-stressed EPCs were treated with insulin, SOD, or 
both. (a) Effect of insulin, SOD, or both on NO production. (b) Effect of insulin, SOD, or both on O2
- generation. (c) Effect of 
insulin, SOD, or both on the number of EPC colonies. Data are expressed as mean percentage ± SEM or mean number ± SEM 
of triplicate measurements in each sample from four independent tests. *P < 0.05, **P < 0.001, ***P < 0.001 vs. glucose-
stressed EPCs. NS represents non-significant.Cardiovascular Diabetology 2009, 8:56 http://www.cardiab.com/content/8/1/56
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